SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir ($PLTR) is trending amid a mixed sentiment, with some traders pointing to a recent report highlighting security flaws in its battlefield communication system while others dismiss it as a hit piece designed to create a buying opportunity. The community is actively debating the company's valuation and future growth prospects in the AI space, with some calling it overvalued and others believing it has significant long-term potential. Despite the debate, some are taking advantage of the dip and loading up on shares, anticipating a rebound.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending after announcing a partnership with Perplexity AI to enhance content discovery and bundle services, sparking community excitement about AI integration. Discussions also revolve around Rumble's ties to cryptocurrency through Tether and potential benefits from a Trump administration. Some traders are eyeing a potential short squeeze given the high short interest.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as users highlight its association with weed culture and its potential for growth, drawing comparisons to Bitcoin. Community members emphasize Weedcoin's focus on freedom, natural growth, and cultural connection, promoting it as more than just a cryptocurrency. Discussions also involve community links and contract addresses.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

QCLS is trending as traders discuss its pivot to quantum computing for crypto applications, focusing on the potential of LightSolver's technology. The community is weighing the company's prospects in the quantum and blockchain sectors, drawing comparisons to similar stocks. Some are watching for a potential short squeeze due to its low float and threshold list status.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to a recent surge in quantum computing stocks, fueled by a $5.7 million sale of two quantum computers. Community discussions revolve around the stock's high valuation and potential for a short squeeze, with bullish investors targeting higher prices while bears anticipate a significant correction. The broader context involves the rapidly growing quantum computing sector and its speculative nature.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience is trending as traders discuss its potential for a squeeze, with some anticipating a rise to $10 or even $20. This speculation follows news of FDA Fast Track designation for ALTO-101 and investors are actively monitoring chat rooms, hoping for a breakout. The community also discusses the company's financials, pipeline and potential readouts.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc is trending due to Citron Research's positive outlook, sparking significant trading volume and community discussion about a potential short squeeze. Community members are debating the company's long-term prospects, comparing it to other telehealth plays, and speculating on factors such as potential acquisitions and partnerships. Overall, the conversation centers on whether Teladoc is undervalued and poised for a breakout.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending as the community discusses its potential for further gains, with some drawing comparisons to past runs of high-performing stocks. Bullish sentiment is fueled by expectations of filling a price gap and reaching higher price ranges. Some traders are also pointing to defensive rotation into healthcare amid broader market concerns, while others cite the potential impact of tariffs on the healthcare sector.

Epsium Enterprise Ltd. operates as a holding company, which engages in import trading and distribution of wines and spirits. It offers a range of products, including Chinese liquor, French cognac, Scottish whisky, fine wines, champagne, and other miscellaneous alcoholic beverages. Its brands include Moutai, Xijiu, Wuliangye, Remy Martin Cognac, Macallan, Cointreau, Piper Heidsieck Champagne, French Fine Wines, Red and White Wines. The company was founded by Son I Tam on March 24, 2020 and is headquartered in Macau.

Epsium Enterprise Ltd. - Ordinary Shares - Class A

Epsium Enterprise Ltd.

Epsium Enterprise Ltd. ($EPSM) is trending due to a volatile trading pattern, marked by frequent trading halts and significant price swings, reminiscent of other high-flying stocks. Community chatter revolves around whether the stock is a pump-and-dump scheme, with some anticipating a massive sell-off while others hope for continued upward momentum. The stock's connection to the Chinese booze market and its small float are also fueling speculation and trading activity.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is trending amid general excitement in the quantum computing sector, with community members highlighting its potential for energy-efficient solutions. Some traders are discussing potential breakouts and short squeezes, while others compare QBTS to other quantum and AI stocks. Recent news and government initiatives in quantum tech appear to be driving interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Cara Therapeutics, Inc. (CARA) traded 10% higher on Monday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.caratherapeutics.com/news-releases/news-release-details/cara-therapeutics-announces-1-3-reverse-stock-split-connection">announced</a> that its board of directors has approved a 1-for-3 reverse stock split of its outstanding shares of common stock.Cara’s common stock is expected to begin trading on a reverse stock split adjusted basis at the opening bell on Wednesday.The company’s common stock will trade under the new name “Tvardi Therapeutics, Inc.” and under the new symbol “TVRD” upon the closing of its merger with privately held, clinical-stage, biopharmaceutical company Tvardi Therapeutics, Inc, the company said.The two companies announced a merger in December. As per the agreement, Cara Therapeutics stockholders are expected to own about 17% of the combined company, and pre-merger Tvardi Therapeutics investors are expected to own approximately 83% of the combined company.On Tuesday evening, every three issued and outstanding shares of Cara’s common stock will automatically be combined into one, effectively reducing the number of issued and outstanding shares of the company's common stock from about 4.6 million to 1.5 million.The company said that fractional shares will not be issued as part of the reverse stock split; instead, entitled shareholders will receive a cash payment.Cara said that after the merger closes, the combined company's total outstanding common stock is expected to be approximately 9.4 million shares.On Stocktwits, retail sentiment around Cara jumped from ‘neutral’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:648/153;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_14_at_1_24_29_PM_png_3d87e8bbd9.webp" alt="CARA's Sentiment Meter and Message Volume as of 1:25 p.m. ET on April 14, 2025 | Source: Stocktwits" width="648" height="153"><figcaption>CARA's Sentiment Meter and Message Volume as of 1:25 p.m. ET on April 14, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/CARA">CARA stock</a> is up by about 1% year-to-date but down by about 37% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ny-fed-survey-of-consumer-expectations/chfCQEoRbaa">NY Fed Survey Of Consumer Expectations Shows Short-Term Inflation Expectations Rose, Unemployment Worries Hit COVID-19 Levels</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Cara Therapeutics Stock Jumps 10% After Announcing 1-for-3 Reverse Stock Split: Retail Sentiment Soars

On Tuesday evening, every three issued and outstanding shares of CARA’s common stock will automatically be combined into one, effectively reducing the number of issued and outstanding shares of the company's common stock from about 4.6m to 1.5m.

Equity

On Tuesday evening, every three issued and outstanding shares of CARA’s common stock will automatically be combined into one, effectively reducing the number of issued and outstanding shares of the company's common stock from about 4.6 million to 1.5 million.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BLUE, VOXX, CARA, CYTH on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BLUE, VOXX, CARA, CYTH on Behalf of Shareholders SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BLUE, VOXX, CARA, CYTH on Behalf of...

CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed merger of Cara Therapeutics, Inc. (NasdaqCM: CARA) and...

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates ML, PWOD, NURO, CARA on Behalf of Shareholders

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates ML, PWOD, NURO, CARA on Behalf of Shareholders SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates ML, PWOD, NURO, CARA on Behalf of Shareholders PR...

CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick and Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PDCO, NURO, PWOD, CARA on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PDCO, NURO, PWOD, CARA on Behalf of Shareholders SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PDCO, NURO, PWOD, CARA on Behalf of...

$HAREHOLDER ALERT: The MandA Class Action Firm Investigates the Merger of Cara Therapeutics, Inc. - CARA

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Cara Therapeutics, Inc. - CARA $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Cara Therapeutics, Inc...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NURO, CARA, ZUO, BMTX on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NURO, CARA, ZUO, BMTX on Behalf of Shareholders SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NURO, CARA, ZUO, BMTX on Behalf of...

CARA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cara Therapeutics, Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Cara Therapeutics, Inc. (NASDAQ: CARA) and Tvardi Therapeutics, Inc. is fair to Cara shareholders. Upon...

Shareholder Alert: Ademi LLP Investigates Whether Cara Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

Ademi LLP is investigating Cara (NASDAQ: CARA) for possible breaches of fiduciary duty and other violations of law in its transaction with Tvardi. Click here to learn how to join our investigation...

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. The company was founded in 2017 and is headquartered in Sugar Land, TX.

Cara Therapeutics Inc

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Current Price	$39.69
Prev Close	$37.37
Open	$39.30
Dividend Yield	0.00%
50-Day Moving Average	$30.17
Beta	1.01
Avg. Volume	60,286.76
PE Ratio	-2.14

52-Week High	$40.77
52-Week Low	$8.13
Market Capitalization	$350.43M
EPS (Annual)	-$46.60
Price to Book	10.64
Revenue Per Employee	$713,700.00
Enterprise Value/EBITDA	N/A

CARA
Cara Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CARA News

CARA Cara Therapeutics Inc